SVB Meltdown Brings Another Blow to Cash-Starved Biotech Industry

Like technology companies, biotech companies found themselves in a tough spot trying to decide what to do with money held at SVB, “an important financial partner” for the industry, John Maraganore, the former Alnylam Pharmaceuticals Inc. chief who’s involved with multiple investment firms and biotech boards, said in an interview.